… We analyzed the EGFR mutation pattern of 79 cases of NSCLC harboring EGFR mutations
and … data for patients with NSCLCs with compound EGFR mutations treated with EGFR TKIs. …

… of tyrosine kinase inhibitors (TKIs) that target the EGFR in … The discovery of somatic mutations
in EGFR that correlated … with the presence of EGFR mutations and objective responses to …

… The importance of EGFR to lung cancers supports the … Tyrosine kinase inhibitors (TKIs)
have been used to treat the cancer harboring EGFR mutations or aberrant activation of EGFR. …

… part of the tyrosine kinase domain of the … EGFR tyrosine kinase inhibitor (TKI), gefitinib,
compared with standard chemotherapy as first line therapy for patients harboring EGFR mutations …

… (EGFR) activating mutations and the demonstration of efficacy of EGFR tyrosine kinase inhibitors
… Several phase III studies have demonstrated the effectiveness of EGFR TKIs, becoming …

… EGFR-mutant lung cancers, we found an inverse relationship between TMB and clinical benefit
of EGFR-tyrosine kinase inhibitors (EGFR… mechanism, we find that mutations in TP53 are …

… response to EGFR TKIs and the presence of EGFR mutations was confirmed in … EGFR
mutation status. This meta-analysis demonstrated that EGFR mutations predict response to EGFR …

… a variety of novel EGFR resistance mutations. We confirmed that … irreversible kinase inhibitors
is significantly affected by mutation … can influence the EGFR mutation spectrum induced by …

… tyrosine kinase inhibitors (EGFR TKIs), gefitinib and erlotinib, are reversible competitive
inhibitors of the tyrosine kinase domain of EGFR … Somatic activating mutations of the EGFR gene, …

… mutations at exons 18, 19, and 21 of the EGFR gene are usually sensitive to treatments with
tyrosine kinase inhibitors (… , despite the presence of an EGFR mutation, and approximately 20…